Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
US10584164B2 · kind B2 · utility
8Cited by
50References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2019 |
| Grant date | Mar 10, 2020 |
| Priority date | — |
| Expiry date | Jan 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.